ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK

Journal of Lipid Research

Volumn 54, Issue 8, 2013, Pages 2095-2108

  Filippov, Sergey ^a   Pinkosky, Stephen L ^a   Lister, Richard J ^a   Pawloski, Catherine ^a   Hanselman, Jeffrey C ^a   Cramer, Clay T ^a   Srivastava, Rai Ajit K ^a   Hurley, Timothy R ^a   Bradshaw, Cheryl D ^a   Spahr, Mark A ^a   Newton, Roger S ^a  

^a Esperion Therapeutics Inc   (United States)

Author keywords

Adipose tissue; AMP activated protein kinase; Cardiometabolic risk factors; Cytokines; Drug therapy; Hypolipidemic drugs; Liver kinase B1; Macrophages monocytes; Mitogenactivated protein kinases

Indexed keywords

8 HYDROXY 2,2,14,14 TETRAMETHYLPENTADECANEDIOIC ACID; CHEMOKINE; CYTOKINE; ETC 1002; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTERLEUKIN 6; LIVER KINASE B1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN KINASE LKB1; SMALL INTERFERING RNA; THIOGLYCOLIC ACID; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG FORMULATION; DYSLIPIDEMIA; ENZYME ACTIVATION; ENZYME ACTIVITY; EPIDIDYMIS FAT; GENE SILENCING; IMMUNE RESPONSE; IN VIVO STUDY; INFLAMMATION; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; LYMPHOCYTE HOMING; MACROPHAGE; METABOLIC SYNDROME X; MONOCYTE; MOUSE; NONHUMAN; OBESITY; PERITONEAL CAVITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SOFT TISSUE INFLAMMATION;

EID: 84881255684     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M035212     Document Type: Article

References (59)

1. Ford, E. S., W. H. Giles, and W. H. Dietz.2002.Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA.287 : 356-359.
2. Olefsky, J. M., and C. K. Glass.2010.Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 72 : 219-246.
3. Rocha, V. Z., and P. Libby.2009.Obesity, inflammation, and atherosclerosis. Nat. Rev. Cardiol. 6 : 399-409.
4. Goyal, R., A. F. Faizy, S. S. Siddiqui, and M. Singhai.2012.Evaluation of TNF-alpha and IL-6 levels in obese and non-obese diabetics: Preand postinsulin effects. N. Am. J. Med. Sci. 4 : 180-184.
5. Ridker, P. M., N. Rifai, M. Pfeffer, F. Sacks, S. Lepage, and E. Braunwald.2000.Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation.101 : 2149-2153.
6. Fernandez-Real, J. M. 2006.Genetic predispositions to low-grade inflammation and type 2 diabetes. Diabetes Technol. Ther. 8 : 55-66.
7. Davies, R. W., G. A. Wells, A. F. Stewart, J. Erdmann, S. H. Shah, J. F. Ferguson, A. S. Hall, S. S. Anand, M. S. Burnett, S. E. Epstein, et al. 2012.A genome-wide association study for coronary artery disease identifi es a novel susceptibility locus in the major histocompatibility complex. Circ Cardiovasc Genet.5 : 217-225.
8. Larsen, C. M., M. Faulenbach, A. Vaag, A. Volund, J. A. Ehses, B. Seifert, T. Mandrup-Poulsen, and M. Y. Donath.2007.Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356 : 1517-1526.
9. Donath, M. Y., and S. E. Shoelson.2011.Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 11 : 98-107.
10. Goldfine, A. B., V. Fonseca, and S. E. Shoelson.2011.Therapeutic approaches to target inflammation in type 2 diabetes. Clin. Chem. 57 : 162-167.
11. Charo, I. F., and R. Taub.2011.Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat. Rev. Drug Discov. 10 : 365-376.
12. Pinkosky, S. L., S. Filippov, A. R. Srivastava, J. C. Hanselman, C. D. Bradshaw, T. R. Hurley, C. T. Cramer, M. A. Spahr, A. F. Brant, J. L. Houghton, et al.2013.AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J. Lipid Res. 54 : 134-151.
13. Srivastava, R. A., T. R. Hurley, A. F. Brant, C. D. Bradshaw, J. C. Hanselman, C. Baker, M. Naples, K. Adeli, and R. S. Newton.2011. A novel small molecule, ETC-1002, lowers proatherogenic lipoproteins, reduces adiposity, and improves hepatic steatosis in a hyperlipidemic hamster model. (Abstract in Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB) Scientific Sessions. Orlando, Florida, November 12-16, 2011).
14. Hanselman, J. C., C. D. Bradshaw, A. F. Brant, C. T. Cramer, T. R. Hurley, S. L. Pinkosky, M. A. Spahr, J. G. Washburn, R. S. Newton, and R. A. K. Srivastava. 2011.ETC-1002 reduces circulating and hepatic triglyceride content and improves glycemic control in KKAy mice. (Abstract in Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB) Scientific Meeting. Chicago, Illinois, April 30, 2011).
15. Cramer, C. T., R. A. Srivastava, J. Lutostanski, C. L. Bisgaier, and R. S. Newton.2011.ETC-1002: A novel small molecule inhibitor of lipogenesis improves plasma lipid profile and inhibits atherosclerosis progression in LDLr-/-mouse by lipid-dependent and independent mechanisms. Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB) Scientific Meeting. Chicago, Illinois, April 29, 2011.
16. Hardie, D. G. 2011.AMP-activated protein kinase: An energy sensor that regulates all aspects of cell function. Genes Dev. 25 : 1895-1908.
17. Salminen, A., J. M. Hyttinen, and K. Kaarniranta.2011.AMPactivated protein kinase inhibits NF-kappaB signaling and inflammation: Impact on healthspan and lifespan. J. Mol. Med. (Berl.).89 : 667-676.
18. Srivastava, R. A., S. L. Pinkosky, S. Filippov, J. C. Hanselman, C. T. Cramer, and R. S. Newton.2012.AMP-activated protein kinase: An emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases. J. Lipid Res. 53 : 2490-2514.
19. Ballantyne, C. M., M. Davidson, D. MacDougall, J. Margulies, and L. DiCarlo.2012.ETC-1002 lowers LDL-C and beneficially modulates other cardio-metabolic risk factors in hypercholesterolemic subjects with either normal or elevated triglycerides. J. Am. Coll. Cardiol. 59 : E1625-E1625.
20. Rogers, A. M., and M. G. Shlipak.2009.C-reactive protein, statins, and cardiovascular risk: What can JUPITER teach us? Am. J. Kidney Dis. 53 : 737-740.
21. Liao, J. K. 2009.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. Curr. Atheroscler. Rep. 11 : 243-244.
22. Bai, A., A. G. Ma, M. Yong, C. R. Weiss, Y. Ma, Q. Guan, C. N. Bernstein, and Z. Peng.2010.AMPK agonist downregulates innate and adaptive immune responses in TNBS-induced murine acute and relapsing colitis. Biochem. Pharmacol. 80 : 1708-1717.
23. Zhao, X., J. W. Zmijewski, E. Lorne, G. Liu, Y. J. Park, Y. Tsuruta, and E. Abraham.2008.Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 295 : L497-L504.
24. Alba, G., R. El Bekay, M. Alvarez-Maqueda, P. Chacon, A. Vega, J. Monteseirin, C. Santa Maria, E. Pintado, F. J. Bedoya, R. Bartrons, et al.2004.Stimulators of AMP-activated protein kinase inhibit the respiratory burst in human neutrophils. FEBS Lett. 573 : 219-225.
25. Giri, S., N. Nath, B. Smith, B. Viollet, A. K. Singh, and I. Singh. 2004.5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside inhibits proinflammatory response in glial cells: A possible role of AMP-activated protein kinase. J. Neurosci. 24 : 479-487.
26. Arai, M., M. Uchiba, H. Komura, Y. Mizuochi, N. Harada, and K. Okajima.2010.Metformin, an antidiabetic agent, suppresses the production of tumor necrosis factor and tissue factor by inhibiting early growth response factor-1 expression in human monocytes in vitro. J. Pharmacol. Exp. Ther. 334 : 206-213.
27. Kanellis, J., R. K. Kandane, D. Etemadmoghadam, S. A. Fraser, P. F. Mount, V. Levidiotis, B. E. Kemp, and D. A. Power.2006.Activators of the energy sensing kinase AMPK inhibit random cell movement and chemotaxis in U937 cells. Immunol. Cell Biol. 84 : 6-12.
28. Yang, Z., B. B. Kahn, H. Shi, and B. Z. Xue.2010.Macrophage alpha1 AMP-activated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J. Biol. Chem. 285 : 19051-19059.
29. Sag, D., D. Carling, R. D. Stout, and J. Suttles.2008.Adenosine 5 '-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J. Immunol. 181 : 8633-8641.
30. Jeong, H. W., K. C. Hsu, J. W. Lee, M. Ham, J. Y. Huh, H. J. Shin, W. S. Kim, and J. B. Kim.2009.Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am. J. Physiol. Endocrinol. Metab. 296 : E955-E964.
31. Galic, S., M. D. Fullerton, J. D. Schertzer, S. Sikkema, K. Marcinko, C. R. Walkley, D. Izon, J. Honeyman, Z. P. Chen, B. J. van Denderen, et al.2011.Hematopoietic AMPK beta1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity. J. Clin. Invest. 121 : 4903-4915.
32. Cramer, C. T., B. Goetz, K. L. Hopson, G. J. Fici, R. M. Ackermann, S. C. Brown, C. L. Bisgaier, W. G. Rajeswaran, D. C. Oniciu, and M. E. Pape.2004.Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome. J. Lipid Res. 45 : 1289-1301.
33. Filippov, S., I. Caras, R. Murray, L. M. Matrisian, H. A. Chapman, Jr ., S. Shapiro, and S. J. Weiss.2003.Matrilysin-dependent elastolysis by human macrophages. J. Exp. Med. 198 : 925-935.
34. Davies, S. P., D. Carling, M. R. Munday, and D. G. Hardie.1992. Diurnal rhythm of phosphorylation of rat liver acetyl-CoA carboxylase by the AMP-activated protein kinase, demonstrated using freezeclamping. Effects of high fat diets. Eur. J. Biochem. 203 : 615-623.
35. Nath, N., S. Giri, R. Prasad, M. L. Salem, A. K. Singh, and I. Singh. 2005.5-aminoimidazole-4-carboxamide ribonucleoside: A novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis. J. Immunol. 175 : 566-574.
36. Koenen, R. R., and C. Weber.2011.Chemokines: Established and novel targets in atherosclerosis. EMBO Mol. Med. 3 : 713-725.
37. Sadik, C. D., and A. D. Luster.2012.Lipid-cytokine-chemokine cascades orchestrate leukocyte recruitment in inflammation. J. Leukoc. Biol. 91 : 207-215.
38. Alexander, A., and C. L. Walker.2011.The role of LKB1 and AMPK in cellular responses to stress and damage. FEBS Lett. 585 : 952-957.
39. Blagih, J., C. M. Krawczyk, and R. G. Jones.2012.LKB1 and AMPK: Central regulators of lymphocyte metabolism and function. Immunol. Rev. 249 : 59-71.
40. Lumeng, C. N., S. M. Deyoung, J. L. Bodzin, and A. R. Saltiel.2007. Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes.56 : 16-23.
41. Melnicoff, M. J., P. K. Horan, and P. S. Morahan.1989.Kinetics of changes in peritoneal cell populations following acute inflammation. Cell. Immunol. 118 : 178-191.
42. Shimizu-Hirota, R., W. Xiong, B. T. Baxter, S. L. Kunkel, I. Maillard, X. W. Chen, F. Sabeh, R. Liu, X. Y. Li, and S. J. Weiss.2012.MT1-MMP regulates the PI3Kdelta.Mi-2/NuRD-dependent control of macrophage immune function. Genes Dev. 26 : 395-413.
43. Rowe, R. G., and S. J. Weiss.2008.Breaching the basement membrane: Who, when and how? Trends Cell Biol. 18 : 560-574.
44. Van Lint, P., and C. Libert.2007.Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J. Leukoc. Biol. 82 : 1375-1381.
45. Patsouris, D., P. P. Li, D. Thapar, J. Chapman, J. M. Olefsky, and J. G. Neels.2008.Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab. 8 : 301-309.
46. Hawley, S. A., J. Boudeau, J. L. Reid, K. J. Mustard, L. Udd, T. P. Makela, D. R. Alessi, and D. G. Hardie.2003.Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/ beta are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2 : 28.
47. Szekanecz, Z., and A. E. Koch.2004.Therapeutic inhibition of leukocyte recruitment in inflammatory diseases. Curr. Opin. Pharmacol. 4 : 423-428.
48. Zernecke, A., and C. Weber.2010.Chemokines in the vascular inflammatory response of atherosclerosis. Cardiovasc. Res. 86 : 192-201.
49. Lee, J. W., S. S. Choe, H. Jang, J. Kim, H. W. Jeong, H. Jo, K. H. Jeong, S. Tadi, M. G. Park, T. H. Kwak, et al.2012.AMPK activation with glabridin ameliorates adiposity and lipid dysregulation in obesity. J. Lipid Res. 53 : 1277-1286.
50. Fouad, H. H., H. Al-Dera, S. W. Bakhoum, L. A. Rashed, R. H. Sayed, M. A. Rateb, M. A. Haidara, S. Soskic, and E. R. Isenovic. 2010.Levels of sCD40 ligand in chronic and acute coronary syndromes and its relation to angiographic extent of coronary arterial narrowing. Angiology.61 : 567-573.
51. Speidl, W. S., S. P. Kastl, K. Huber, and J. Wojta.2011.Complement in atherosclerosis: Friend or foe? J. Thromb. Haemost. 9 : 428-440.
52. Nguyen, M. T., S. Favelyukis, A. K. Nguyen, D. Reichart, P. A. Scott, A. Jenn, R. Liu-Bryan, C. K. Glass, J. G. Neels, and J. M. Olefsky.2007. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J. Biol. Chem. 282 : 35279-35292.
53. Saberi, M., N. B. Woods, C. de Luca, S. Schenk, J. C. Lu, G. Bandyopadhyay, I. M. Verma, and J. M. Olefsky.2009.Hematopoietic cell-specific deletion of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice. Cell Metab. 10 : 419-429.
54. Ehses, J. A., G. Lacraz, M. H. Giroix, F. Schmidlin, J. Coulaud, N. Kassis, J. C. Irminger, M. Kergoat, B. Portha, F. Homo-Delarche, et al.2009.IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc. Natl. Acad. Sci. USA.106 : 13998-14003.
55. Hotamisligil, G. S., N. S. Shargill, and B. M. Spiegelman.1993. Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science.259 : 87-91.
56. Viollet, B., B. Guigas, N. Sanz Garcia, J. Leclerc, M. Foretz, and F. Andreelli.2012.Cellular and molecular mechanisms of metformin: An overview. Clin. Sci. (Lond.).122 : 253-270.
57. Carter, A. M., C. E. Bennett, J. A. Bostock, and P. J. Grant.2005. Metformin reduces C-reactive protein but not complement factor C3 in overweight patients with Type 2 diabetes mellitus. Diabet. Med. 22 : 1282-1284.
58. Krysiak, R., and B. Okopien.2013.The effect of metformin on monocyte secretory function in simvastatin-treated patients with impaired fasting glucose. Metabolism.62 : 39-43.
59. Krysiak, R., and B. Okopien.2012.Lymphocyte-suppressing and systemic anti-inflammatory effects of high-dose metformin in simvastatin-treated patients with impaired fasting glucose. Atherosclerosis. 225 : 403-407.